Next Article in Journal
Cerebellopontine Angle Facial Schwannoma Relapsing Towards Middle Cranial Fossa
Previous Article in Journal
Kawasaki Disease: Giant Aneurysm with a Large Thrombus of the Left Coronary Artery
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Clinics and Practice
Volume 1
Issue 2
10.4081/cp.2011.e28
clinpract-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Clinics and Practice is published by MDPI from Volume 11 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

Early Viral Kinetics and Response to Treatment in a Hepatitis C Virus Genotype 5 Infected Patient

by
Emanuele Durante-Mangoni
*,
Domenico Iossa
and
Umberto Malgeri
Internal Medicine, 2nd University of Naples, Monaldi Hospital, Napoli, Italy
*
Author to whom correspondence should be addressed.
Clin. Pract. 2011, 1(2), e28; https://doi.org/10.4081/cp.2011.e28
Submission received: 24 March 2011 / Revised: 24 March 2011 / Accepted: 22 April 2011 / Published: 29 April 2011

Abstract

Genotype 5 hepatitis C has been poorly studied despite its worldwide spread. We have analyzed the early kinetics of genotype 5 hepatitis C virus RNA during pegylated interferon/ribavirin treatment in a 59-year-old man with active liver necroinflammatory changes and advanced liver fibrosis. The patient had a high viral load but a small serum level of hepatitis C core antigen. On combination antiviral treatment with pegylated-interferon alpha 2a, 180 μg/week, and ribavirin, 1200 mg/day, the patient experienced an impressive reduction in serum HCV RNA as early as day 2 of treatment and eventually became a sustained virological responder. Our viral kinetics data support previous clinical studies showing HCV genotype 5 could be as intrinsically sensitive to interferon as HCV genotypes 2 and 3.
Keywords: hepatitis C; chronic; pegylated interferon alpha-2a; ribavirin; treatment outcome hepatitis C; chronic; pegylated interferon alpha-2a; ribavirin; treatment outcome

Share and Cite

MDPI and ACS Style

Durante-Mangoni, E.; Iossa, D.; Malgeri, U. Early Viral Kinetics and Response to Treatment in a Hepatitis C Virus Genotype 5 Infected Patient. Clin. Pract. 2011, 1, e28. https://doi.org/10.4081/cp.2011.e28

AMA Style

Durante-Mangoni E, Iossa D, Malgeri U. Early Viral Kinetics and Response to Treatment in a Hepatitis C Virus Genotype 5 Infected Patient. Clinics and Practice. 2011; 1(2):e28. https://doi.org/10.4081/cp.2011.e28

Chicago/Turabian Style

Durante-Mangoni, Emanuele, Domenico Iossa, and Umberto Malgeri. 2011. "Early Viral Kinetics and Response to Treatment in a Hepatitis C Virus Genotype 5 Infected Patient" Clinics and Practice 1, no. 2: e28. https://doi.org/10.4081/cp.2011.e28

APA Style

Durante-Mangoni, E., Iossa, D., & Malgeri, U. (2011). Early Viral Kinetics and Response to Treatment in a Hepatitis C Virus Genotype 5 Infected Patient. Clinics and Practice, 1(2), e28. https://doi.org/10.4081/cp.2011.e28

Article Metrics

Back to TopTop